TY - JOUR
T1 - Measurement properties of the ASAS Health Index
T2 - Results of a global study in patients with axial and peripheral spondyloarthritis
AU - Kiltz, Uta
AU - Van Der Heijde, Désirée
AU - Boonen, Annelies
AU - Akkoc, Nurullah
AU - Bautista-Molano, Wilson
AU - Burgos-Vargas, Ruben
AU - Wei, James Cheng Chung
AU - Chiowchanwisawakit, Praveena
AU - Dougados, Maxime
AU - Duruoz, M. Tuncay
AU - Elzorkany, Bassel Kamal
AU - Gaydukova, Inna
AU - Gensler, Lianne S.
AU - Gilio, Michele
AU - Grazio, Simeon
AU - Gu, Jieruo
AU - Inman, Robert D.
AU - Kim, Tae Jong
AU - Navarro-Compan, Victoria
AU - Marzo-Ortega, Helena
AU - Ozgocmen, Salih
AU - Pimentel Dos Santos, Fernando
AU - Schirmer, Michael
AU - Stebbings, Simon
AU - Van Den Bosch, Filip E.
AU - Van Tubergen, Astrid
AU - Braun, Juergen
PY - 2018/9
Y1 - 2018/9
N2 - Objectives: To evaluate construct validity, interpretability, reliability and responsiveness as well as determination of cut-off points for good and poor health within the original English version and the 18 translations of the disease-specific Assessment of Spondyloarthritis international Society Health Index (ASAS HI) in 23 countries worldwide in patients with spondyloarthritis (SpA). Methods: A representative sample of patients with SpA fulfilling the ASAS classification criteria for axial (axSpA) or peripheral SpA was used. The construct validity of the ASAS HI was tested using Spearman correlation with several standard health outcomes for axSpA. Test-retest reliability was assessed by intraclass correlation coefficients (ICCs) in patients with stable disease (interval 4-7 days). In patients who required an escalation of therapy because of high disease activity, responsiveness was tested after 2-24weeks using standardised response mean (SRM). Results: Among the 1548 patients, 64.9% were men, with a mean (SD) age 42.0 (13.4) years. Construct validity ranged from low (age: 0.10) to high (Bath AnkylosingSpondylitisFunctioning Index: 0.71). Internal consistency was high (Cronbach's α of 0.93). The reliability among 578 patients was good (ICC=0.87 (95% CI 0.84 to 0.89)). Responsiveness among 246 patients was moderate-large (SRM= '0.44 for non-steroidal anti-inflammatory drugs, '0.69 for conventional synthetic disease-modifying antirheumatic drug and '0.85 for tumour necrosis factor inhibitor). The smallest detectable change was 3.0. Values ≤5.0 have balanced specificity to distinguish good health as opposed to moderate health, and values ≥12.0 are specific to represent poor health as opposed to moderate health. Conclusions: The ASAS HI proved to be valid, reliable and responsive. It can be used to evaluate the impact of SpA and its treatment on functioning and health. Furthermore, comparison of disease impact between populations is possible.
AB - Objectives: To evaluate construct validity, interpretability, reliability and responsiveness as well as determination of cut-off points for good and poor health within the original English version and the 18 translations of the disease-specific Assessment of Spondyloarthritis international Society Health Index (ASAS HI) in 23 countries worldwide in patients with spondyloarthritis (SpA). Methods: A representative sample of patients with SpA fulfilling the ASAS classification criteria for axial (axSpA) or peripheral SpA was used. The construct validity of the ASAS HI was tested using Spearman correlation with several standard health outcomes for axSpA. Test-retest reliability was assessed by intraclass correlation coefficients (ICCs) in patients with stable disease (interval 4-7 days). In patients who required an escalation of therapy because of high disease activity, responsiveness was tested after 2-24weeks using standardised response mean (SRM). Results: Among the 1548 patients, 64.9% were men, with a mean (SD) age 42.0 (13.4) years. Construct validity ranged from low (age: 0.10) to high (Bath AnkylosingSpondylitisFunctioning Index: 0.71). Internal consistency was high (Cronbach's α of 0.93). The reliability among 578 patients was good (ICC=0.87 (95% CI 0.84 to 0.89)). Responsiveness among 246 patients was moderate-large (SRM= '0.44 for non-steroidal anti-inflammatory drugs, '0.69 for conventional synthetic disease-modifying antirheumatic drug and '0.85 for tumour necrosis factor inhibitor). The smallest detectable change was 3.0. Values ≤5.0 have balanced specificity to distinguish good health as opposed to moderate health, and values ≥12.0 are specific to represent poor health as opposed to moderate health. Conclusions: The ASAS HI proved to be valid, reliable and responsive. It can be used to evaluate the impact of SpA and its treatment on functioning and health. Furthermore, comparison of disease impact between populations is possible.
KW - ankylosing spondylitis
KW - outcomes research
KW - spondyloarthritis
UR - http://www.scopus.com/inward/record.url?scp=85049042058&partnerID=8YFLogxK
U2 - 10.1136/annrheumdis-2017-212076
DO - 10.1136/annrheumdis-2017-212076
M3 - Article
AN - SCOPUS:85049042058
VL - 77
SP - 1311
EP - 1317
JO - Annals of the rheumatic diseases
JF - Annals of the rheumatic diseases
SN - 0003-4967
IS - 9
ER -